Differential role of N-methyl-D-aspartate receptor subunits 2A and 2B in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits

Neuroscience

Volumn 163, Issue 4, 2009, Pages 1181-1191

  Anastasio, N C ^a   Xia, Y ^a   O'connor, Z R ^a   Johnson, K M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apoptosis; Locomotor sensitization; N methyl D aspartate receptor; Phencyclidine; Schizophrenia

Indexed keywords

CASPASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHENCYCLIDINE; 5 (ALPHA METHYL 4 BROMOBENZYLAMINO)PHOSPHONOMETHYL 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 5-(ALPHA-METHYL-4-BROMOBENZYLAMINO)PHOSPHONOMETHYL-1,4-DIHYDROQUINOXALINE-2,3-DIONE; AMINO ACID RECEPTOR BLOCKING AGENT; CASP3 PROTEIN, RAT; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2A NMDA RECEPTOR; NR2B NMDA RECEPTOR; PIPERIDINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; LOCOMOTION; MALE; NERVE CELL; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; NEWBORN; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CASPASE 3; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; LOCOMOTION; MALE; NEURONS; PHENCYCLIDINE; PIPERIDINES; QUINOXALINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 76249112700     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.07.058     Document Type: Article

References (66)

1. Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N (1994) Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 347:150-160.
2. Anastasio NC, Johnson KM (2008a) Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol Biochem Behav 90:569-577.
3. Anastasio NC, Johnson KM (2008b) Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J Neurochem 104:1210-1218.
4. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12:1099-1102.
5. Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL (1997) GABAA, NMDA and AMPA receptors: a developmentally regulated "menage a trois". Trends Neurosci 20:523-529.
6. Chaperon F, Muller W, Auberson YP, Tricklebank MD, Neijt HC (2003) Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol 14:477-487.
7. Chen Q, Reiner A (1996) Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res 743:346-352.
8. Chen Q, Veenman CL, Reiner A (1996) Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptormediated excitotoxicity. Neuroscience 73:715-731.
9. Choquet D, Triller A (2003) The role of receptor diffusion in the organization of the postsynaptic membrane. Nat Rev Neurosci 4:251-265.
10. Cousins SL, Papadakis M, Rutter AR, Stephenson FA (2008) Differential interaction of NMDA receptor subtypes with the post-synaptic density-95 family of membrane associated guanylate kinase proteins. J Neurochem 104:903-913.
11. Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327-335.
12. De Vry J, Jentzsch KR (2003) Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 14:229-235.
13. Deng YP, Xie JP, Wang HB, Lei WL, Chen Q, Reiner A (2007) Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats. J Chem Neuroanat 33:167-192.
14. Dong YN, Waxman EA, Lynch DR (2004) Interactions of postsynaptic density-95 and the NMDA receptor 2 subunit control calpain-mediated cleavage of the NMDA receptor. J Neurosci 24:11035-11045.
15. du Bois TM, Deng C, Han M, Newell KA, Huang XF (2009) Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. Eur Neuropsychopharmacol 19(4):256-265.
16. du Bois TM, Huang XF (2007) Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev 53:260-270.
17. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141:508-516.
18. Frizelle PA, Chen PE, Wyllie DJ (2006) Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl)-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: implications for studies of synaptic transmission. Mol Pharmacol 70:1022-1032.
19. Hardingham GE, Bading H (2002) Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim Biophys Acta 1600:148-153.
20. Hardingham GE, Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26:81-89.
21. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5:405-414.
22. Honey CR, Miljkovic Z, MacDonald JF (1985) Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett 61:135-139.
23. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70-74.
24. Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 572: 789-798.
25. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
26. Johnson KM, Jones SM (1990) Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750.
27. Keppel G (1982) Design and analysis: a researcher's handbook. Englewood Cliffs, NJ: Prentice-Hall.
28. Kim E, Sheng M (2004) PDZ domain proteins of synapses. Nat Rev Neurosci 5:771-781.
29. Kohr G (2006) NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 326:439-446.
30. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, et al. (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36-41.
31. Laurie DJ, Seeburg PH (1994) Ligand affinities at recombinant Nmethyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol 268:335-345.
32. Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399:A7-A14.
33. Lei G, Xia Y, Johnson KM (2008) The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology 33:1343-1353.
34. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304:1021-1024.
35. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27:2846-2857.
36. Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 11:81-86.
37. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962) Model psychoses and schizophrenia. Am J Psychiatry 119:61-67.
38. Lynch DR, Guttmann RP (2001) NMDA receptor pharmacology: perspectives from molecular biology. Curr Drug Targets 2:215-231.
39. MacDonald JF, Miljkovic Z, Pennefather P (1987) Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 58:251-266.
40. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
41. Neyton J, Paoletti P (2006) Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci 26:1331-1333.
42. Olney JW, Farber NB (1995a) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
43. Olney JW, Farber NB (1995b) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345.
44. Olney JW, Ikonomidou C, Mosinger JL, Frierdich G (1989) MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J Neurosci 9:1701-1704.
45. Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P, Ikonomidou C (2002) Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 12:488-498.
46. Prybylowski K, Chang K, Sans N, Kan L, Vicini S, Wenthold RJ (2005) The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47:845-857.
47. Sans N, Petralia RS, Wang YX, Blahos J 2nd, Hell JW, Wenthold RJ (2000) A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J Neurosci 20:1260-1271.
48. Sherwood NM, Timiras PS (1970) A stereotaxic atlas of the developing rat brain. Berkeley, CA: University of California Press.
49. Sircar R, Follesa P, Ticku MK (1996) Postnatal phencyclidine treatment differentially regulates N-methyl-D-aspartate receptor subunit mRNA expression in developing rat cerebral cortex. Brain Res Mol Brain Res 40:214-220.
50. Soriano FX, Hardingham GE (2007) Compartmentalized NMDA receptor signalling to survival and death. J Physiol 584:381-387.
51. Strous RD, Javitt DC (1996) The N-methyl-D-aspartate receptor and schizophrenia. Isr J Med Sci 32:275-281.
52. Suvarna N, Borgland SL, Wang J, Phamluong K, Auberson YP, Bonci A, Ron D (2005) Ethanol alters trafficking and functional N-methyl-D-aspartate receptor NR2 subunit ratio via H-Ras. J Biol Chem 280:31450-31459.
53. Thomas CG, Miller AJ, Westbrook GL (2006) Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol 95:1727-1734.
54. Tovar KR, Westbrook GL (1999) The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19:4180-4188.
55. Tovar KR, Westbrook GL (2002) Mobile NMDA receptors at hippocampal synapses. Neuron 34:255-264.
56. van Zundert B, Yoshii A, Constantine-Paton M (2004) Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends Neurosci 27:428-437.
57. Vanhoutte P, Bading H (2003) Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol 13:366-371.
58. Verma A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379.
59. Vickers AEM, Fisher RL (2004) Organ slices for the evaluation of human drug toxicity. Chem Biol Interact 150:87-96.
60. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535-550.
61. Wang CZ, Johnson KM (2005) Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81:284-292.
62. Wang CZ, Johnson KM (2007) The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32:1178-1194.
63. Williams K (2001) Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets 2:285-298.
64. Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM (2008) Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogenactivated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. J Pharmacol Exp Ther 326:838-848.
65. Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P, Bading H (2007) Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 53:549-562.
66. Zhou M, Baudry M (2006) Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci 26:2956-2963.